Publications
396 results found
Brains KE, Lifford K, Carter B, et al., 2014, IMPACT OF LUNG CANCER SCREENING IN A HIGH-RISK POPULATION: THE UK LUNG SCREENING (UKLS) TRIAL, INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE, Vol: 21, Pages: S81-S81, ISSN: 1070-5503
Yancheva S, Velani A, Rice A, et al., 2014, Bombesin staining in Neuroendocrine cell Hyperplasia of Infancy (NEHI) and other childhood Interstitial Lung Diseases (chILD), VIRCHOWS ARCHIV, Vol: 465, Pages: S30-S30, ISSN: 0945-6317
Lunt A, Desai SR, Wells AU, et al., 2014, Pulmonary function, CT and echocardiographic abnormalities in sickle cell disease, THORAX, Vol: 69, Pages: 746-751, ISSN: 0040-6376
- Author Web Link
- Cite
- Citations: 31
Camus P, von der Thusen J, Hansell DM, et al., 2014, Pleuroparenchymal fibroelastosis: one more walk on the wild side of drugs?, EUROPEAN RESPIRATORY JOURNAL, Vol: 44, Pages: 289-296, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 46
Desai SR, Edey AJ, Hansell DM, et al., 2014, Morphologic Predictors of a Microbiological Yield in Patients With a Tree-in-Bud Pattern on Computed Tomography, JOURNAL OF THORACIC IMAGING, Vol: 29, Pages: 240-245, ISSN: 0883-5993
- Author Web Link
- Cite
- Citations: 4
Zoumot Z, Boutou AK, Gill SS, et al., 2014, Mycobacterium avium complex infection in non-cystic fibrosis bronchiectasis, RESPIROLOGY, Vol: 19, Pages: 714-722, ISSN: 1323-7799
- Author Web Link
- Cite
- Citations: 51
Richeldi L, Cottin V, Flaherty KR, et al., 2014, Design of the INPULSIS<SUP>™</SUP> trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis, RESPIRATORY MEDICINE, Vol: 108, Pages: 1023-1030, ISSN: 0954-6111
- Author Web Link
- Cite
- Citations: 72
Richeldi L, du Bois RM, Raghu G, et al., 2014, Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis, NEW ENGLAND JOURNAL OF MEDICINE, Vol: 370, Pages: 2071-2082, ISSN: 0028-4793
- Author Web Link
- Cite
- Citations: 2764
Dhariwal J, Tennant RC, Hansell DM, et al., 2014, Smoking Cessation in COPD Causes a Transient Improvement in Spirometry and Decreases Micronodules on High-Resolution CT Imaging, CHEST, Vol: 145, Pages: 1006-1015, ISSN: 0012-3692
- Author Web Link
- Cite
- Citations: 19
Jacob J, Nair A, Hansell DM, 2014, High-Resolution Computed Tomography of the Pulmonary Manifestations of Connective Tissue Diseases, SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 35, Pages: 166-180, ISSN: 1069-3424
- Author Web Link
- Cite
- Citations: 5
Spagnolo P, Sverzellati N, Wells AU, et al., 2014, Imaging aspects of the diagnosis of sarcoidosis, EUROPEAN RADIOLOGY, Vol: 24, Pages: 807-816, ISSN: 0938-7994
- Author Web Link
- Cite
- Citations: 31
Keir GJ, Maher TM, Ming D, et al., 2014, Rituximab in severe, treatment-refractory interstitial lung disease, RESPIROLOGY, Vol: 19, Pages: 353-359, ISSN: 1323-7799
- Author Web Link
- Cite
- Citations: 176
Baldwin DR, Hansell DM, Duffy SW, et al., 2014, Lung cancer screening with low dose computed tomography, BMJ-BRITISH MEDICAL JOURNAL, Vol: 348, ISSN: 1756-1833
- Author Web Link
- Cite
- Citations: 1
Keir GJ, Garfield B, Hansell DM, et al., 2014, Cyclical caspofungin for chronic pulmonary aspergillosis in sarcoidosis, THORAX, Vol: 69, Pages: 287-U93, ISSN: 0040-6376
- Author Web Link
- Cite
- Citations: 24
Walsh SLF, Sverzellati N, Devaraj A, et al., 2014, Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants, THORAX, Vol: 69, Pages: 216-222, ISSN: 0040-6376
- Author Web Link
- Cite
- Citations: 145
McRonald FE, Yadegarfar G, Baldwin DR, et al., 2014, The UK Lung Screen (UKLS): Demographic Profile of First 88,897 Approaches Provides Recommendations for Population Screening, CANCER PREVENTION RESEARCH, Vol: 7, Pages: 362-371, ISSN: 1940-6207
- Author Web Link
- Cite
- Citations: 98
Walsh SLF, Wells AU, Sverzellati N, et al., 2014, An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study, The Lancet Respiratory Medicine, Vol: 2, Pages: 123-130, ISSN: 2213-2600
BackgroundMortality in pulmonary sarcoidosis is highly variable and a reliable prognostic algorithm for disease staging and for guiding management decisions is needed. The objective of this study is to derive and test a staging system for determining prognosis in pulmonary sarcoidosis.MethodsWe identified the prognostic value of high-resolution computed tomography (HRCT) patterns and pulmonary function tests, including the composite physiological index (CPI) in patients with pulmonary sarcoidosis. We integrated prognostic physiological and HRCT variables to form a clinical staging algorithm predictive of mortality in a test cohort. The staging system was externally validated in a separate cohort by the same methods of discrimination used in the primary analysis and tested for clinical applicability by four test observers.FindingsThe test cohort included 251 patients with pulmonary sarcoidosis in the study referred to the Sarcoidosis clinic at the Royal Brompton Hospital, UK, between Jan 1, 2000, and June 30, 2010. The CPI was the strongest predictor of mortality (HR 1·04, 95% CI 1·02–1·06, p<0·0001) in the test cohort. An optimal CPI threshold of 40 units was identified (HR 4·24, 2·84–6·33, p<0·0001). The CPI40, main pulmonary artery diameter to ascending aorta diameter ratio (MPAD/AAD), and an extent of fibrosis threshold of 20% were combined to form a staging algorithm. When assessed in the validation cohort (n=252), this staging system was strikingly more predictive of mortality than any individual variable alone (HR 5·89, 2·68–10·08, p<0·0001). The staging system was successfully applied to the test and validation cohorts combined, by two radiologists and two physicians.InterpretationA clear prognostic separation of patients with pulmonary sarcoidosis is provided by a simple staging system integrating the CPI and two HRCT variables.FundingNational Insti
Nair A, Hansell DM, 2014, High-Resolution Computed Tomography Features of Smoking-Related Interstitial Lung Disease, SEMINARS IN ULTRASOUND CT AND MRI, Vol: 35, Pages: 59-71, ISSN: 0887-2171
- Author Web Link
- Cite
- Citations: 16
Walsh SLF, Hansell DM, 2014, High-Resolution CT of Interstitial Lung Disease: A Continuous Evolution, SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 35, Pages: 129-144, ISSN: 1069-3424
- Author Web Link
- Cite
- Citations: 20
Zappala CJ, Desai SR, Copley SJ, et al., 2014, Accuracy of Individual Variables in the Monitoring of Long-term Change in Pulmonary Sarcoidosis as Judged by Serial High-Resolution CT Scan Data, CHEST, Vol: 145, Pages: 101-107, ISSN: 0012-3692
Field JK, Devaraj A, Baldwin DR, et al., 2014, UK Lung Cancer Screening trial (UKLS): Prevalence data at baseline, LUNG CANCER, Vol: 83, Pages: S24-S25, ISSN: 0169-5002
- Author Web Link
- Cite
- Citations: 4
Kokosi M, Schreiber B, Haddock J, et al., 2014, Lung Parenchyma Density Gradient At Computed Tomography In Patients With Idiopathic Pulmonary Arterial Hypertension, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 189, ISSN: 1073-449X
Field JK, Hansell DM, Duffy SW, et al., 2013, CT screening for lung cancer: countdown to implementation, LANCET ONCOLOGY, Vol: 14, Pages: E591-E600, ISSN: 1470-2045
- Author Web Link
- Cite
- Citations: 47
Antoniou KM, Walsh SL, Hansell DM, et al., 2013, Smoking-related emphysema is associated with idiopathic pulmonary fibrosis and rheumatoid lung, RESPIROLOGY, Vol: 18, Pages: 1191-1196, ISSN: 1323-7799
- Author Web Link
- Cite
- Citations: 41
Irving SJ, Ives A, Davies G, et al., 2013, Lung Clearance Index and High-Resolution Computed Tomography Scores in Primary Ciliary Dyskinesia, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 188, Pages: 545-549, ISSN: 1073-449X
- Author Web Link
- Cite
- Citations: 63
Abdullah R, Ming D, Keir G, et al., 2013, Rituximab in severe, treatment-refractory interstitial lung disease, EUROPEAN RESPIRATORY JOURNAL, Vol: 42, ISSN: 0903-1936
Hansell DM, 2013, Classification of Diffuse Lung Diseases: Why and How, RADIOLOGY, Vol: 268, Pages: 628-640, ISSN: 0033-8419
- Author Web Link
- Cite
- Citations: 13
Lota HK, Keir GJ, Hansell DM, et al., 2013, Novel use of rituximab in hypersensitivity pneumonitis refractory to conventional treatment, THORAX, Vol: 68, ISSN: 0040-6376
- Author Web Link
- Cite
- Citations: 39
Sykes A, Brooks T, Dusmet M, et al., 2013, Inhalational anthrax in a vaccinated soldier, EUROPEAN RESPIRATORY JOURNAL, Vol: 42, Pages: 285-287, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 5
Horsley AR, Davies JC, Gray RD, et al., 2013, Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation, Thorax, Vol: 68, Pages: 532-539, ISSN: 1468-3296
Background Clinical trials in cystic fibrosis (CF) have been hindered by the paucity of well characterised and clinically relevant outcome measures.Aim To evaluate a range of conventional and novel biomarkers of CF lung disease in a multicentre setting as a contributing study in selecting outcome assays for a clinical trial of CFTR gene therapy.Methods A multicentre observational study of adult and paediatric patients with CF (>10 years) treated for a physician-defined exacerbation of CF pulmonary symptoms. Measurements were performed at commencement and immediately after a course of intravenous antibiotics. Disease activity was assessed using 46 assays across five key domains: symptoms, lung physiology, structural changes on CT, pulmonary and systemic inflammatory markers.Results Statistically significant improvements were seen in forced expiratory volume in 1 s (p<0.001, n=32), lung clearance index (p<0.01, n=32), symptoms (p<0.0001, n=37), CT scores for airway wall thickness (p<0.01, n=31), air trapping (p<0.01, n=30) and large mucus plugs (p=0.0001, n=31), serum C-reactive protein (p<0.0001, n=34), serum interleukin-6 (p<0.0001, n=33) and serum calprotectin (p<0.0001, n=31).Discussion We identify the key biomarkers of inflammation, imaging and physiology that alter alongside symptomatic improvement following treatment of an acute CF exacerbation. These data, in parallel with our study of biomarkers in patients with stable CF, provide important guidance in choosing optimal biomarkers for novel therapies. Further, they highlight that such acute therapy predominantly improves large airway parameters and systemic inflammation, but has less effect on airway inflammation.
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.